DVAX
Price
$10.28
Change
+$0.02 (+0.19%)
Updated
Aug 28, 04:59 PM (EDT)
Capitalization
1.2B
63 days until earnings call
ESPR
Price
$2.21
Change
+$0.02 (+0.92%)
Updated
Aug 28, 04:59 PM (EDT)
Capitalization
445.59M
69 days until earnings call
Interact to see
Advertisement

DVAX vs ESPR

Header iconDVAX vs ESPR Comparison
Open Charts DVAX vs ESPRBanner chart's image
Dynavax Technologies
Price$10.28
Change+$0.02 (+0.19%)
Volume$42.14K
Capitalization1.2B
Esperion Therapeutics
Price$2.21
Change+$0.02 (+0.92%)
Volume$46.11K
Capitalization445.59M
DVAX vs ESPR Comparison Chart in %
Loading...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DVAX vs. ESPR commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DVAX is a Buy and ESPR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (DVAX: $10.26 vs. ESPR: $2.18)
Brand notoriety: DVAX and ESPR are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: DVAX: 98% vs. ESPR: 93%
Market capitalization -- DVAX: $1.2B vs. ESPR: $445.59M
DVAX [@Pharmaceuticals: Generic] is valued at $1.2B. ESPR’s [@Pharmaceuticals: Generic] market capitalization is $445.59M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.8B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DVAX’s FA Score shows that 0 FA rating(s) are green whileESPR’s FA Score has 0 green FA rating(s).

  • DVAX’s FA Score: 0 green, 5 red.
  • ESPR’s FA Score: 0 green, 5 red.
According to our system of comparison, ESPR is a better buy in the long-term than DVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DVAX’s TA Score shows that 4 TA indicator(s) are bullish while ESPR’s TA Score has 2 bullish TA indicator(s).

  • DVAX’s TA Score: 4 bullish, 6 bearish.
  • ESPR’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, both DVAX and ESPR are a bad buy in the short-term.

Price Growth

DVAX (@Pharmaceuticals: Generic) experienced а -1.54% price change this week, while ESPR (@Pharmaceuticals: Generic) price change was +6.34% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.00%. For the same industry, the average monthly price growth was +11.42%, and the average quarterly price growth was +84.24%.

Reported Earning Dates

DVAX is expected to report earnings on Oct 30, 2025.

ESPR is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+2.00% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DVAX($1.2B) has a higher market cap than ESPR($446M). ESPR YTD gains are higher at: -0.909 vs. DVAX (-19.655). ESPR has higher annual earnings (EBITDA): -32.5M vs. DVAX (-34.26M). DVAX has more cash in the bank: 614M vs. ESPR (86.1M). DVAX has less debt than ESPR: DVAX (285M) vs ESPR (302M). DVAX has higher revenues than ESPR: DVAX (316M) vs ESPR (268M).
DVAXESPRDVAX / ESPR
Capitalization1.2B446M270%
EBITDA-34.26M-32.5M105%
Gain YTD-19.655-0.9092,162%
P/E Ratio54.60N/A-
Revenue316M268M118%
Total Cash614M86.1M713%
Total Debt285M302M94%
FUNDAMENTALS RATINGS
DVAX vs ESPR: Fundamental Ratings
DVAX
ESPR
OUTLOOK RATING
1..100
5820
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
37
Fair valued
PROFIT vs RISK RATING
1..100
85100
SMR RATING
1..100
94100
PRICE GROWTH RATING
1..100
6235
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ESPR's Valuation (37) in the Biotechnology industry is somewhat better than the same rating for DVAX (71). This means that ESPR’s stock grew somewhat faster than DVAX’s over the last 12 months.

DVAX's Profit vs Risk Rating (85) in the Biotechnology industry is in the same range as ESPR (100). This means that DVAX’s stock grew similarly to ESPR’s over the last 12 months.

DVAX's SMR Rating (94) in the Biotechnology industry is in the same range as ESPR (100). This means that DVAX’s stock grew similarly to ESPR’s over the last 12 months.

ESPR's Price Growth Rating (35) in the Biotechnology industry is in the same range as DVAX (62). This means that ESPR’s stock grew similarly to DVAX’s over the last 12 months.

DVAX's P/E Growth Rating (98) in the Biotechnology industry is in the same range as ESPR (100). This means that DVAX’s stock grew similarly to ESPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DVAXESPR
RSI
ODDS (%)
Bearish Trend 4 days ago
67%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
68%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
76%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 16 days ago
75%
Bullish Trend 7 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 17 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ICFSX10.29N/A
N/A
ICON Consumer Select Institutional
JNBCX10.29N/A
N/A
JPMorgan Income Builder C
FTPSX93.21N/A
N/A
Invesco Technology R6
NBRFX13.77N/A
N/A
Neuberger Berman Real Estate Tr
AIMOX17.87-0.05
-0.28%
AQR International Momentum Style I

DVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, DVAX has been loosely correlated with ACET. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DVAX jumps, then ACET could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DVAX
1D Price
Change %
DVAX100%
-1.72%
ACET - DVAX
39%
Loosely correlated
+2.57%
SNDL - DVAX
35%
Loosely correlated
+2.43%
AMRX - DVAX
33%
Poorly correlated
-0.21%
ESPR - DVAX
32%
Poorly correlated
-0.46%
BCRX - DVAX
32%
Poorly correlated
-0.70%
More